Wicki A - Search Results

1

Vemurafenib-induced radiation recall dermatitis: case report and review of the literature.

Conen K, Mosna-Firlejczyk K, Rochlitz C, Wicki A, Itin P, Arnold AW, Gross M, Zimmermann F, Zippelius A. Conen K, et al. Among authors: wicki a. Dermatology. 2015;230(1):1-4. doi: 10.1159/000365918. Epub 2014 Nov 29. Dermatology. 2015. PMID: 25472806 Review.

2

Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.

Wicki A, Rochlitz C, Orleth A, Ritschard R, Albrecht I, Herrmann R, Christofori G, Mamot C. Wicki A, et al. Clin Cancer Res. 2012 Jan 15;18(2):454-64. doi: 10.1158/1078-0432.CCR-11-1102. Epub 2011 Nov 7. Clin Cancer Res. 2012. PMID: 22065082

3

Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.

Mamot C, Ritschard R, Wicki A, Küng W, Schuller J, Herrmann R, Rochlitz C. Mamot C, et al. Among authors: wicki a. J Drug Target. 2012 Jun;20(5):422-32. doi: 10.3109/1061186X.2012.680960. Epub 2012 Apr 23. J Drug Target. 2012. PMID: 22519893

4

Targeted therapies in breast cancer.

Wicki A, Rochlitz C. Wicki A, et al. Swiss Med Wkly. 2012 Apr 27;142:w13550. doi: 10.4414/smw.2012.13550. eCollection 2012. Swiss Med Wkly. 2012. PMID: 22544433 Free article. Review.

5

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.

Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, Hilker C, Deuster S, Herrmann R, Rochlitz C. Mamot C, et al. Among authors: wicki a. Lancet Oncol. 2012 Dec;13(12):1234-41. doi: 10.1016/S1470-2045(12)70476-X. Epub 2012 Nov 13. Lancet Oncol. 2012. PMID: 23153506 Clinical Trial.

6

[Melanoma- finally good news].

Wicki A, Arnold AW, Itin PH, Zippelius A. Wicki A, et al. Praxis (Bern 1994). 2013 May 22;102(11):667-70. doi: 10.1024/1661-8157/a001293. Praxis (Bern 1994). 2013. PMID: 23692905 Review. German.

7

Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors.

Wicki A, Wild D, Prêtre V, Mansi R, Orleth A, Reubi JC, Rochlitz C, Mamot C, Mäcke HR, Christofori G. Wicki A, et al. EJNMMI Res. 2014 Feb 16;4(1):9. doi: 10.1186/2191-219X-4-9. EJNMMI Res. 2014. PMID: 24528513 Free PMC article.

8

Pre-existing antihypertensive treatment predicts early increase in blood pressure during bevacizumab therapy: the prospective AVALUE cohort study.

Wicki A, Hermann F, Prêtre V, Winterhalder R, Kueng M, von Moos R, Rochlitz C, Herrmann R. Wicki A, et al. Oncol Res Treat. 2014;37(5):230-6. doi: 10.1159/000362376. Epub 2014 Apr 8. Oncol Res Treat. 2014. PMID: 24853781 Clinical Trial.

9

Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial.

Wicki A, Ritschard R, Loesch U, Deuster S, Rochlitz C, Mamot C. Wicki A, et al. Int J Pharm. 2015 Apr 30;484(1-2):8-15. doi: 10.1016/j.ijpharm.2015.02.034. Epub 2015 Feb 18. Int J Pharm. 2015. PMID: 25701632

10

Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy.

Xue G, Zippelius A, Wicki A, Mandalà M, Tang F, Massi D, Hemmings BA. Xue G, et al. Among authors: wicki a. J Natl Cancer Inst. 2015 Jun 11;107(7):djv171. doi: 10.1093/jnci/djv171. Print 2015 Jul. J Natl Cancer Inst. 2015. PMID: 26071042 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Search Page

Filters